Medicaid's prior authorization program and access to atypical antipsychotic medications
Medicaid's prior authorization program and access to atypical antipsychotic medications
复制标题
DOI：
10.1377/hlthaff.26.3.750
复制
发表时间：
2007-05-01
期刊：
影响因子：
9.7
通讯作者：
Fischer, Michael A.
中科院分区：
文献类型：
--
作者：
Polinski, Jennifer M.;Wang, Philip S.;Fischer, Michael A.
州医疗补助计划使用事先授权（PA）来控制药物支出，要求在允许报销之前满足特定条件。PA政策对药物安全新发展的反应程度尚不清楚。2005年4月，美国食品和药物管理局（FDA）发布了一份报告，说明服用非典型抗精神病药物的老年痴呆症患者死亡率增加。一年多过去了，没有一个州改变其PA政策作为回应。我们讨论了医疗补助和其他保险公司在应对新出现的药物安全问题方面的作用，以及他们在权衡药物风险和收益方面的挑战。
State Medicaid programs use prior authorization (PA) to control drug spending by requiring that specific conditions be met before allowing reimbursement. The extent to which PA policies respond to new developments concerning medication safety is not known. In April 2005 the Food and Drug Administration (FDA) issued an advisory describing increased mortality among elderly people with dementia taking atypical antipsychotics. More than a year later, no state had changed its PA policy in response. We discuss the roles of Medicaid and other insurers in responding to emerging drug safety issues and their challenges in weighing drug risks and benefits.